[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hematopoietic-and-lymphoid-cell-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hematopoietic-and-lymphoid-cell-neoplasm":24},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,29,0,25,[9,41,66,87,108,126,144,225,245,263,299,323,343,378,402,422,441,472,491,513,536,556,574,594,618],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100191818","molecular-testing-for-the-md-anderson-cancer-center-personalized-cancer-therapy-program-100191818",false,"NCT01772771","Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program","Inclusion Criteria:\n\n* Patients must have histologically, radiographic, or cytologically documented cancer, suspected glioma, sarcoma, melanoma or hematologic cancer. Patients with benign tumors may also be consented at the discretion of the attending physician if molecular profiling is felt to have potential clinical implications.\n* Patients must have the ability to understand and the willingness to sign a written informed consent document\n* Patients may be consented without confirming the amount and quality of archival diagnostic or residual tissue available. However, research testing will only be performed on patients who have sufficient archived diagnostic tissue or residual tissue banked in one of the authorized tissue banks at MD Anderson available to proceed with testing. The extent of testing may be modified based on amount of tissue available. If any new tissue acquisition including a biopsy and\u002For surgical resection etc. is being ordered for clinical care or another research study, or an operation is being performed testing can be ordered on that sample\n* Circulating cell-free deoxyribonucleic acid (cfDNA) Cohort: Circulating cell-free DNA next generation sequencing (NGS) testing will be performed with the Clinical Laboratory Improvement Act (CLIA)-certified Guardant360 panel (or equivalent) for select patients. This particular cohort of research collaboration will be supported by Guardant Health, Inc. at no charge to MD Anderson. Patients who are being considered for enrollment into clinical trials in the next 2 lines of therapy may be enrolled. Selected patients may have cfDNA, circulating RNA \u002Fexosome\u002Fcirculating tumor cell testing approaches performed on alternate platforms (eg Foundation ACT)","ALL",{"count":18,"type":19},12000,"ESTIMATED","OBSERVATIONAL","This study performs standardized testing of tumor tissue samples to learn which genes are mutated (have changed) in order to provide personalized cancer therapy options to cancer patients at MD Anderson. This may help doctors use testing information on tumors to identify clinical trials that may be most relevant to patients. Researchers may also use the information learned from this study to develop a database of the different kinds of mutations in cancer-related genes.",[23,24,25,26,27],"Glioma","Hematopoietic and Lymphoid Cell Neoplasm","Malignant Solid Neoplasm","Melanoma","Sarcoma","RECRUITING","2026-08-20",{"date":31,"type":32},"2026-08-21","ACTUAL",{"date":34,"type":32},"2012-03-01",{"date":36,"type":19},"2033-03-01",{"name":38,"class":39},"M.D. Anderson Cancer Center","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":40},"100419622","early-phase-1-addition-of-cord-blood-tissue-derived-mesenchymal-stromal-cells-to-ruxolitinib-for-the-treatment-of-steroid-refractory-acute-graft-versus-host-disease-100419622","NCT04744116","Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease","A Randomized Controlled Pilot Study of Two Doses of Cord Blood Tissue-Derived Mesenchymal Stromal Cells Combined With Ruxolitinib Versus Ruxolitinib Alone for Therapy of Steroid-Refractory Acute Graft Versus Host Disease","Inclusion Criteria:\n\n1. Participants between the ages of 12 years and 80 years (inclusive).\n2. Steroid refractory grades II-IV acute GVHD of the Lower GI tract or Liver (including those developing these manifestations after previous acute GVHD of skin) secondary to allogeneic HCT or donor lymphocyte infusion. (Grading, see Appendix I) GVHD with: No improvement after treatment with methylprednisolone at ≥ 2.0 mg\u002Fkg\u002Fday or equivalent for minimum 7 days, or progressive symptoms after minimum 3 days, or a flare in acute GVHD while on systemic steroids. Participants must have had a biopsy that suggests GVHD; a repeat biopsy to enroll on the study is not necessary.\n3. Karnofsky\u002FLansky Performance score of at least 30 at the time of study entry.\n4. Participants who are women of childbearing potential, must be non-pregnant, not breast-feeding, and use adequate contraception. Male patients must use adequate contraception\n5. Participants (or legal representative where appropriate) must be capable of providing written informed consent, and assent if indicated.\n\nExclusion Criteria:\n\n1. De novo chronic GVHD\n2. Isolated acute GVHD of skin\n3. Secondary systemic therapy for acute GVHD ruxolitinib greater than 96 hours before initiation of therapy.\n4. Primary treatment with agents other than alpha-1 antitrypsin (AAT) glucocorticoids and ruxolitinib.\n5. Participants with uncontrolled infections will be excluded. Infections are considered controlled if appropriate therapy has been instituted and, at the time of enrollment, no signs of progression are present. Progression of infection is defined as hemodynamic instability attributable to sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.\n6. Adult and pediatric patients with cognitive impairments and\u002For any serious unstable pre-existing medical condition or psychiatric disorder that can interfere with safety or with obtaining informed consent or compliance with study procedures.\n7. Participants with significant supplemental oxygen requirement defined as \\>6 L oxygen by nasal cannula.\n8. Participants with known allergy to bovine or porcine products.","12 Years","80 Years",{"count":51,"type":19},24,"INTERVENTIONAL",[54],"EARLY_PHASE1","This early phase I trial is to find out the effect of adding cord blood tissue-derived mesenchymal stromal cells (cb-MSCs) to ruxolitinib in treating patients with acute graft versus host disease that does not respond to steroid therapy (steroid-refractory). Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. cb-MSCs are a type of tissue helper cell that can be removed from donated umbilical cord blood tissue and grown into many different cell types that can be used to treat cancer and other disease, such as graft versus host disease. This trial aims to learn if adding cb-MSCs to ruxolitinib may help control steroid-refractory acute graft versus host disease.",[24,57],"Steroid Refractory Graft Versus Host Disease","2026-08-17",{"date":60,"type":32},"2026-08-18",{"date":62,"type":32},"2021-02-17",{"date":64,"type":19},"2032-03-31",{"name":38,"class":39},{"id":67,"slug":68,"hasResults":12,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":12,"sex":16,"minAge":73,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":52,"phases":76,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},"100530249","early-phase-1-alteplase-through-an-indwelling-pleural-catheter-for-the-management-of-symptomatic-septated-malignant-pleural-effusion-100530249","NCT06184321","Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion","A Randomized Trial of Alteplase Versus Placebo Through an Indwelling Pleural Catheter for Management of Symptomatic Septated MPE","Inclusion Criteria:\n\n* Referral to pulmonary services for inability to drain fully via IPC\n* Presence of a symptomatic septated pleural effusion\n* A pleural effusion of significant moderate to large volume based on:\n\n  * Chest radiograph: effusion filling \\>= 1\u002F3 of the hemithorax, or\n  * Computed tomography (CT)-scan: AP depth of the effusion \\>= 1\u002F3 of the AP dimension on the axial image superior to the hemidiaphragm, including atelectatic lung surrounded by effusion, or\n  * Ultrasound: effusion spanning at least three intercostal spaces, with a \\>= 3 cm in at least one intercostal space, while the patient sits upright\n* Age \\> 18\n* Borg score \\>= 3\n* Absence of a blocked IPC as demonstrated by a flush with 20 cc of saline x1 without resistance\n* Presence of septated effusion based on ultrasound (US) and chest CT\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Study subject has any disease or condition that interferes with safe completion of the study including:\n\n  * Uncorrectable coagulopathy based on criteria followed by cardiopulmonary center for procedures.\n  * Active bleeding\n  * Known allergic reaction to thrombolytics\n* Pleural effusion is smaller than expected on bedside pre-procedure ultrasound\n* No septations and\u002For no loculations on bedside pre-procedure ultrasound\n* Patient is asymptomatic\n* Blocked IPC as determined by saline flush","18 Years",{"count":75,"type":19},30,[54],"This study investigates whether alteplase can help to improve pleural fluid drainage and dyspnea (breathlessness) in patients with non-draining malignant pleural effusion. Alteplase helps dissolve blood clots and is used to treat heart attacks, strokes, and clots in the lungs. Alteplase may help to control symptoms of breathlessness.",[24,25],"2026-08-13",{"date":58,"type":32},{"date":82,"type":32},"2023-08-17",{"date":84,"type":19},"2027-02-02",{"name":38,"class":39},2,{"id":88,"slug":89,"hasResults":12,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":12,"sex":16,"minAge":73,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":52,"phases":96,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":40},"100422139","expressive-writing-for-the-management-of-stress-in-cancer-survivors-100422139","NCT04776941","Expressive Writing for the Management of Stress in Cancer Survivors","COVID-19: A Virtual Feasibility Study to Manage Stress","Inclusion Criteria:\n\n* At least 18 years old\n* Have a diagnosis of cancer within the past 3 years\n* Are able to speak and read in English\n* Have access to a computer or smart phone with internet connection\n* All disease sites and all cancer stages are eligible for enrollment\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Non-English speakers will be excluded because this is a feasibility study that will enroll only a limited number of participants",{"count":95,"type":19},414,[97],"NA","This clinical trial evaluates the effect of expressive writing for the management of stress in cancer survivors. Cancer diagnosis and treatment are associated with increased stress in cancer survivors related to concerns about family, career, relationships, finances, side effects of treatment, and death. This stress can be further exacerbated by social upheavals such as the COVID-19 pandemic. For safety reasons, many patients are isolated with restricted access to in-person health care and reduced social interaction with family and friends. Together with the economic uncertainties that come with this pandemic, these factors are likely to increase cancer survivors' stress levels. Expressive writing may provide a medium through which cancer survivors confront stressors and find meaning in their experience. The goal of this trial is to learn more about the experiences of cancer survivors during stressful times.",[24,25],"2026-08-12",{"date":102,"type":32},"2026-08-14",{"date":104,"type":32},"2020-08-07",{"date":106,"type":19},"2028-12-31",{"name":38,"class":39},{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":125,"locationsCount":40},"100447598","complications-and-clinical-response-in-cancer-patients-treated-with-anti-vegf-related-therapies-100447598","NCT05108519","Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies","A Prospective Study Evaluating Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies","Inclusion Criteria:\n\n* Patients must be able to understand and be willing to sign a written informed consent document\n* Patients must be receiving any anti-VEGF-related regimen in monotherapy or combination therapy",{"count":116,"type":19},170,"This study collects information about complications and clinical response in cancer patients treated with anti-VEGF-related therapies. This study aims to observe side effects that may happen to patients with advanced cancer who are treated with anti-VEGF related therapy. This may help doctors learn if there are any relationships between these side effects and how the disease may respond to treatment.",[24,25],"2026-08-07",{"date":121,"type":32},"2026-08-10",{"date":123,"type":32},"2019-04-08",{"date":84,"type":19},{"name":38,"class":39},{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":133,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":143,"locationsCount":40},"100440986","the-impact-of-covid-19-on-pulmonary-procedures-100440986","NCT05022446","The Impact of COVID-19 on Pulmonary Procedures","The Impact of COVID-19 on Pulmonary Procedures: A Nationwide Survey","Inclusion Criteria:\n\n* Pulmonologists that are members of the American Association of Bronchology and Interventional Pulmonology (AABIP) and\u002For the American College of Chest Physicians (ACCP)\n* These organizations were chosen because their member databases are composed of pulmonologists in the United States (U.S.) that perform the pulmonary procedures described in this survey. Letters of approval will be obtained from these organizations and provided to the MD Anderson Institutional Review Board (IRB). Once the MD Anderson IRB approves this survey study, the survey will be sent to the relevant subcommittees of these organizations for their electronic dissemination to their membership\n\nExclusion Criteria:\n\nNone",true,{"count":135,"type":19},250,"This study investigates the changes in practice by pulmonary procedural programs across the United States as they faced the coronavirus pandemic. Information gathered from this study may help guide pulmonary programs on a wider scale and improve their practice. The study may also help researchers understand where they should focus research efforts to better respond to a pandemic in the future.",[138,24,25],"COVID-19 Infection",{"date":121,"type":32},{"date":141,"type":32},"2020-11-11",{"date":84,"type":19},{"name":38,"class":39},{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":133,"sex":16,"minAge":151,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":224},"100464928","collecting-blood-samples-from-patients-with-and-without-cancer-to-evaluate-tests-for-early-cancer-detection-100464928","NCT05334069","Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","Blinded Reference Set for Multicancer Early Detection Blood Tests","Inclusion Criteria:\n\n* Participants with a cancer diagnosis: Documentation of disease:\n\n  * Histologic documentation: Histologically confirmed diagnosis of invasive cancer\n  * Stage: Stage I-IV per American Joint Committee on Cancer (AJCC) 7th edition, with the exception of patients with leukemia, lymphoma, and multiple myeloma\n\n    * For leukemia: Type (chronic lymphocytic leukemia \\[CLL\\], chronic myeloid leukemia \\[CML\\], acute lymphoblastic lymphoma \\[ALL\\], acute myeloid leukemia \\[AML\\])\n    * For lymphoma: Stage I-IV based on Ann Arbor staging\n    * For multiple myeloma: Stage I, II, III based on Revised International Staging System (RISS)\n  * One of the following tumor types:\n\n    * Colorectal\n    * Bladder\n    * Head and neck\n    * Hepatobiliary\n    * Lung\n    * Lymphoma\n    * Leukemia\n    * Ovary \\*\\*\\* For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment\n    * Pancreas \\*\\*\\* For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment\n    * Multiple myeloma\n    * Gastric, esophageal or gastroesophageal\n    * Breast\n    * Thyroid\n    * Kidney\n\n      * For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment\n    * Endometrium\n    * Prostate\n    * Melanoma\n\n      \\*\\*\\* For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment\n    * Sarcoma\n* Participants with a cancer diagnosis: No prior definitive systemic or local anti-cancer intervention\n* Participants with a cancer diagnosis: Age \\>= 40 and =\\\u003C 75\n* Participants with a cancer diagnosis: No known current pregnancy by self-report\n* Participants with a cancer diagnosis: No known or prior history of in situ or invasive malignancy (excluding in situ non-melanoma skin cancers) other than the current cancer diagnosis\n* Participants with a cancer diagnosis: Willingness to provide blood samples for research use\n* Participants with a cancer diagnosis: Absence of medical contraindications to a research blood draw volume of 60 mL\n* Participants with a cancer diagnosis: No history of organ transplantation\n* Participants with a cancer diagnosis: Ability to read and comprehend English or Spanish\n\n  \\* Eligibility is restricted to individuals who can comprehend and read English or Spanish given that participation in the study will require the ability to read and complete questionnaires that are available only in those two languages\n* Participants without a cancer diagnosis and without suspicion of cancer: Age \\>= 40 and =\\\u003C 75\n* Participants without a cancer diagnosis and without suspicion of cancer: No known current pregnancy by self-report\n* Participants without a cancer diagnosis and without suspicion of cancer: No known or prior history of in situ or invasive malignancy (excluding in situ non-melanoma skin cancers)\n* Participants without a cancer diagnosis and without suspicion of cancer: Willingness to provide blood samples for research use\n* Participants without a cancer diagnosis and without suspicion of cancer: Absence of medical contraindications to a research blood draw volume of 60 mL\n* Participants without a cancer diagnosis and without suspicion of cancer: No history of organ transplantation\n* Participants without a cancer diagnosis and without suspicion of cancer: Ability to read and comprehend English or Spanish\n\n  \\* Eligibility is restricted to individuals who can comprehend and read English or Spanish given that participation in the study will require the ability to read and complete questionnaires that are available only in those two languages\n* Participants with a high suspicion of cancer: High suspicion of ovarian cancer, pancreatic cancer, kidney cancer, or melanoma by clinical and\u002For radiological assessment, with plans for histologic or cytologic confirmation within 28 days after study blood draw\n\n  \\* Examples of highly suspicious cases include: elevated CA125 and abnormal transvaginal ultrasound, suspicious renal or pancreatic mass on imaging, suspicious cutaneous lesion concerning for melanoma\n* Participants with a high suspicion of cancer: Central review of radiology reports and\u002For clinical documentation conducted by study chairs\n* Participants with a high suspicion of cancer: Age \\>= 40 and =\\\u003C 75\n* Participants with a high suspicion of cancer: No known current pregnancy by self-report\n* Participants with a high suspicion of cancer: No known or prior history of in situ or invasive malignancy (excluding in situ non-melanoma skin cancers) other than the current cancer diagnosis\n* Participants with a high suspicion of cancer: Willingness to provide blood samples for research use\n* Participants with a high suspicion of cancer: Absence of medical contraindications to a research blood draw volume of 60 mL\n* Participants with a high suspicion of cancer: No history or organ transplantation\n* Participants with a high suspicion of cancer: Ability to read and comprehend English or Spanish \\* Eligibility is restricted to individuals who can comprehend and read English and Spanish given that participation in the study will require the ability to read and complete questionnaires that are available only in those two languages","40 Years","75 Years",{"count":154,"type":19},2000,"This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.",[157,158,159,160,161,162,163,164,165,166,24,167,168,169,25,26,170,171,172,173,27,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214],"Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Ann Arbor Stage I Lymphoma","Ann Arbor Stage II Lymphoma","Ann Arbor Stage III Lymphoma","Ann Arbor Stage IV Lymphoma","Chronic Lymphocytic Leukemia","Chronic Myeloid Leukemia","Gastroesophageal Junction Adenocarcinoma","Head and Neck Carcinoma","Invasive Breast Carcinoma","Kidney Carcinoma","Malignant Hepatobiliary Neoplasm","Muscle-Invasive Bladder Carcinoma","RISS Stage I Plasma Cell Myeloma","RISS Stage II Plasma Cell Myeloma","RISS Stage III Plasma Cell Myeloma","Stage I Bladder Cancer AJCC v6 and v7","Stage I Breast Cancer AJCC v7","Stage I Colorectal Cancer AJCC v6 and v7","Stage I Esophageal Cancer AJCC V7","Stage I Gastric Cancer AJCC V7","Stage I Lung Cancer AJCC v7","Stage I Ovarian Cancer AJCC v6 and v7","Stage I Pancreatic Cancer AJCC v6 and v7","Stage I Prostate Cancer AJCC v7","Stage I Uterine Corpus Cancer AJCC v7","Stage II Bladder Cancer AJCC v6 and v7","Stage II Breast Cancer AJCC v6 and v7","Stage II Colorectal Cancer AJCC v7","Stage II Esophageal Cancer AJCC v7","Stage II Gastric Cancer AJCC v7","Stage II Lung Cancer AJCC v7","Stage II Ovarian Cancer AJCC v6 and v7","Stage II Pancreatic Cancer AJCC v6 and v7","Stage II Prostate Cancer AJCC v7","Stage II Uterine Corpus Cancer AJCC v7","Stage III Bladder Cancer AJCC v6 and v7","Stage III Breast Cancer AJCC v7","Stage III Colorectal Cancer AJCC v7","Stage III Esophageal Cancer AJCC v7","Stage III Gastric Cancer AJCC v7","Stage III Lung Cancer AJCC v7","Stage III Ovarian Cancer AJCC v6 and v7","Stage III Pancreatic Cancer AJCC v6 and v7","Stage III Prostate Cancer AJCC v7","Stage III Uterine Corpus Cancer AJCC v7","Stage IV Bladder Cancer AJCC v7","Stage IV Breast Cancer AJCC v6 and v7","Stage IV Colorectal Cancer AJCC v7","Stage IV Esophageal Cancer AJCC v7","Stage IV Gastric Cancer AJCC v7","Stage IV Lung Cancer AJCC v7","Stage IV Ovarian Cancer AJCC v6 and v7","Stage IV Pancreatic Cancer AJCC v6 and v7","Stage IV Prostate Cancer AJCC v7","Stage IV Uterine Corpus Cancer AJCC v7","Thyroid Gland Carcinoma","2026-08-04",{"date":217,"type":32},"2026-08-05",{"date":219,"type":32},"2022-08-18",{"date":221,"type":19},"2027-02-28",{"name":223,"class":39},"Alliance for Clinical Trials in Oncology",744,{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":16,"minAge":73,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":52,"phases":234,"briefSummary":235,"conditions":236,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":40},"100522960","weighted-blanket-use-to-reduce-anxiety-in-oncology-patients-100522960","NCT06089408","Weighted Blanket Use to Reduce Anxiety in Oncology Patients","Weighted Blanket Use in Oncology Patients to Reduce Anxiety","Inclusion Criteria:\n\n* Age 18 years of age and older\n* About to begin either targeted or cytotoxic chemotherapy\n* Able to comprehend and sign a consent form\n* Able to read and complete surveys\n* Alert and oriented\n\nExclusion Criteria:\n\n* Currently using a weighted blanket at home\n* Non-English speaking\n* Peripheral neuropathy\n* Fibromyalgia\n* Open pressure ulcer\n* Recent surgical flap\n* Claustrophobic\n* Weight 45 kg or less",{"count":233,"type":19},114,[97],"This clinical trial compares the effect of using weighted blankets versus regular blankets during first time infusions (e.g. chemotherapy, targeted therapy etc.) to decrease adverse side effects such as anxiety and distress in cancer (oncology) patients. Feeling safe, comforted, and grounded in the world are some of the benefits noted by individuals who use weighted blankets. Deep touch pressure (DTP) has been found to reduce symptoms of stress and anxiety and is defined as a sensation one feels when being hugged, squeezed, or held. DTP affects the nervous system by creating a calming effect which may lower stress and increase feelings of well-being. The use of weighted blankets may help to manage anxiety and distress during chemotherapy or immunotherapy infusions.",[24,25],"2026-08-03",{"date":217,"type":32},{"date":240,"type":32},"2023-08-01",{"date":242,"type":19},"2027-12-31",{"name":244,"class":39},"Ohio State University Comprehensive Cancer Center",{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":12,"sex":16,"minAge":73,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":256,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":40},"100431033","social-relationships-and-accelerated-aging-in-hematopoietic-cell-transplant-survivors-100431033","NCT04892823","Social Relationships and Accelerated Aging in Hematopoietic Cell Transplant Survivors","Accelerated Biological and Phenotypic Aging in Hematopoietic Cell Transplant Survivors: Social Support as a Protective Factor","Inclusion Criteria:\n\n* Aged 18 years and older who are competent to give their informed consent.\n* Ability to read, speak, and understand English.\n* Received a hematopoietic cell transplant within the previous 100 days.\n\nExclusion Criteria:\n\n* Less then Aged 18 years and older who are competent to give their informed consent.\n* Cannot read, speak, and understand English.\n* Has not received a hematopoietic cell transplant within the previous 100 days.",{"count":253,"type":19},110,"This project aims to elucidate the important protective elements of social relationships and identify concrete, modifiable behavioral factors that contribute to biological and phenotypic aging in hematopoietic cell transplantation (HCT) survivors and can be used to develop biologically informed interventions to improve quality of life and prolong the healthspan of individuals with accelerated aging.",[24],{"date":217,"type":32},{"date":258,"type":32},"2021-05-18",{"date":260,"type":19},"2027-07-16",{"name":262,"class":39},"Medical College of Wisconsin",{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":12,"sex":16,"minAge":73,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":52,"phases":272,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":298},"100348403","phase-1-testing-an-immunotherapy-anti-cancer-drug-nivolumab-for-advanced-cancers-in-patients-with-autoimmune-disorders-aim-nivo-100348403","NCT03816345","Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO","A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)","Inclusion Criteria:\n\n* Patients can have either histologically confirmed malignancy that is radiologically evaluable and metastatic or unresectable, or have a malignancy for which a PD-1\u002FPD-L1 inhibitor has been approved in the adjuvant setting, as well as the neoadjuvant or perioperative setting in which such treatment is considered standard of care or has been approved. Eligible tumor types include solid tumors and malignancies in which there is known evidence of clinical activity for single agent PD-1 or PD-L1 antibodies. Nivolumab or other PD1\u002FPD-L1 inhibitors are FDA-approved for the treatment of melanoma, non-small cell lung cancer (NSCLC), Merkel cell cancer, bladder cancer, renal cell carcinoma (RCC), gastric cancer, hepatocellular carcinoma (HCC), cervical cancer, head and neck cancer, Hodgkin lymphoma (HL), metastatic small cell lung cancer (SCLC), and any solid tumor with microsatellite instability (MSI)-high status confirmed. Patients with HL are eligible but must follow standard response criteria. Additional tumor types may be eligible on a case by case basis upon discussion with principal investigator (PI)\n\n  * Patients enrolling on the trial for adjuvant use will be restricted to those with histology for which a PD-1\u002FPD-L1 inhibitor has been approved in the adjuvant setting including but not limited to NSCLC, melanoma, RCC, cervical cancer, and bladder cancer\n  * Patients enrolled on the study can receive Nivolumab with other FDA-approved combinations according to the FDA package insert, including, but not limited to ipilimumab, cabozantinib or chemotherapy\n* Patients who have previously received other forms of immunotherapy (high-dose \\[HD\\] IL-2, IFN, CTLA-4) are allowed. Patients must not have received cytokine immunotherapy for at least 4 weeks before nivolumab administration. Patients who have received prior anti-CTLA4 will be allowed and the washout period is 6 weeks\n* Age \\>= 18 years; children are excluded from this study but may be eligible for future pediatric phase 1 combination trials\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 (Karnofsky \\>= 60)\n* Life expectancy of greater than 12 weeks\n* Leukocytes \\>= 1,000\u002FmcL\n* Absolute neutrophil count \\>= 500\u002FmcL\n* Platelets \\>= 50,000\u002FmcL\n* Total bilirubin =\\\u003C 2 x institutional upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\])\u002Falanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\\u003C 5 x institutional ULN or =\\\u003C 8 x institutional ULN for patients with liver metastases or an autoimmune disease that is contributing to the elevation of these values\n* Creatinine ULN OR glomerular filtration rate (GFR) \\>= 30 mL\u002Fmin (if using the Cockcroft-Gault formula)\n* Human immunodeficiency virus (HIV)-infected patients on effective antiretroviral therapy with undetectable viral load within 6 months are eligible for this trial\n* If evidence of chronic hepatitis B virus (HBV) infection, HBV viral load must be undetectable on suppressive therapy if indicated\n* If history of hepatitis C virus (HCV) infection, must be treated with undetectable HCV viral load\n* Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate central nervous system (CNS) specific treatment is not required and is unlikely to be required for at least 4 weeks (or scheduled assessment after the first cycle of treatment), and a risk-benefit analysis (discussion) by the patient and the investigator favors participation in the clinical trial\n* The effects of nivolumab on the developing human fetus are unknown. For this reason, women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. WOCBP receiving nivolumab will be instructed to adhere to contraception for a period of 5 months after the last dose of investigational product. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of investigational product\n\n  * Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent units of human chorionic gonadotropin \\[HCG\\]) within 24 hours prior to the start of nivolumab. Women must not be breastfeeding. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraception\n  * WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy), tubal ligation, or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU\u002FmL\n  * These durations have been calculated using the upper limit of the half-life for nivolumab (25 days) and are based on the protocol requirement that WOCBP use contraception for 5 half-lives plus 30 days, and men who are sexually active with WOCBP use contraception for 5 half-lives plus 90 days\n  * Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she (or the participating partner) should inform the treating physician immediately. Patients can resume treatment upon termination of a pregnancy or the completion of a successful pregnancy\n* Ability to understand and the willingness to sign a written informed consent document\n* Patients with more than one autoimmune disease are eligible. The treating physician would determine which autoimmune disease is dominant and the patient would be treated under that specific cohort (Please note: Patients with more than one autoimmune disease should receive assessments for all previously diagnosed autoimmune diseases. For example, a patient with psoriasis and IBD might be enrolled in the IBD cohort. Disease assessments for both psoriasis and IBD should be obtained, as per protocol. Case report forms \\[CRFs\\] for all relevant autoimmune diseases should be utilized. However, all additional cohort requirements will be considered optional and only the assessments from the assigned cohort will be considered mandatory)\n* DM\u002FSSc-SPECIFIC INCLUSION: Patients with known SSc or DM according to updated classification criteria (Van den Hoogan et al., Arthritis Rheum 2013;65(11):2737-47; Lundberg et al., A\\&R in press). Overlap features are permitted, but patients must meet criteria for a \"primary diagnosis\" of DM or SSc\n* DM\u002FSSc-SPECIFIC INCLUSION: Patients may be on any concurrent therapy for DM or SSc unless specifically excluded\n* DM\u002FSSc-SPECIFIC INCLUSION: Patients must have a baseline computed tomography (CT) of the chest (within 6 months of study entry)\n* RA-SPECIFIC INCLUSION: Rheumatologist-diagnosed RA requiring prior treatment with disease-modifying antirheumatic drugs (DMARDs) before patient was diagnosed with current malignancy. We recommend, but do not require, documentation for meeting 2010 American College of Rheumatology (ACR)\u002FEuropean League Against Rheumatism (EULAR) classification criteria for RA\n* RA-SPECIFIC INCLUSION: Prednisone up to 10 mg\u002Fday will be allowed. Intraarticular steroids will be allowed for the treatment of new symptomatic joints\n* RA-SPECIFIC INCLUSION: Nonsteroidal anti-inflammatory drugs (NSAIDs) will be allowed\n* SLE-SPECIFIC INCLUSION: SLE diagnosed by a rheumatologist. The patient should meet the revised 1997 American College of Rheumatology (ACR) classification criteria for SLE, but this is not mandatory\n* ULCERATIVE COLITIS (UC)-SPECIFIC INCLUSION: Diagnosis of UC must be made by endoscopy with biopsies\n* UC-SPECIFIC INCLUSION: Complete colonoscopy with biopsies during study screening, within 8 weeks before initial nivolumab administration, or within 4 weeks after initial nivolumab administration\n* UC-SPECIFIC INCLUSION: Patients must test negative for hepatitis B (antigen \\[Ag\\] negative, antibody \\[core (c)Ab\\] negative, antibody \\[surface (s)Ab\\] positive or negative) and Mycobacterium tuberculosis (purified-protein- derivative \\[PPD\\] or enzyme-linked immunospot assay \\[ELISpot or T-spot\\]) or be on appropriate anti-microbial treatment for these infections\n* UC-SPECIFIC INCLUSION: Mild Disease Cohort: Patients must be in clinical remission, defined as a Mayo Clinic score (MCS) of 2 or lower and no subscore higher than 1, and an endoscopic subscore of 0 or 1 either without medications, or treated with 5-ASA derivative, probiotic, or prior fecal transplant\n* UC-SPECIFIC INCLUSION: Moderate Disease Cohort: Patients must be in clinical remission, defined as a MCS of 2 or lower and no subscore higher than 1, and an endoscopic subscore of 0 or 1 on 6-mercaptopurine, azathioprine, methotrexate, or rectal hydrocortisone, budesonide, or one of these medications in combination with any of the medications listed in the Mild cohort\n* UC-SPECIFIC INCLUSION: Severe Disease Cohort (A or B): Patients must either be A) in clinical remission, defined as a MCS of 2 or lower and no subscore higher than 1, and an endoscopic subscore of 0 or 1 on a biologic therapy targeting tumor necrosis alpha (TNF-α) (infliximab, adalimumab, golimumab), α4β7 integrin (vedolizumab), or one of these biologic therapies in combination with any of the medications listed in the Mild or Moderate cohort, or B) have mild active disease defined as a MCS of 3-5 and no subscore higher than 2, and an endoscopic subscore of \\\u003C 2 on one of the medications or combination of medications defined for the Moderate or Mild cohort\n* CROHN'S DISEASE (CD)-SPECIFIC INCLUSION: Complete colonoscopy with biopsies during study screening, within 8 weeks before initial nivolumab administration, or within 4 weeks after initial nivolumab administration\n* CD-SPECIFIC INCLUSION: If patients have prior known disease in the stomach or small intestines, appropriate endoscopic evaluation (esophagogastroduodenoscopy\u002Fvideo capsule endoscopy) and\u002For imaging (computed tomography or magnetic resonance enterography) must also be current within 4 weeks prior to nivolumab administration\n* CD-SPECIFIC INCLUSION: Deep enteroscopy techniques, such as double balloon enteroscopy, will not be required\n* CD-SPECIFIC INCLUSION: Patients must test negative for hepatitis B (sAg negative, cAb negative, sAb positive or negative) and M. tuberculosis (PPD or ELISpot or T-spot) or be on appropriate anti-microbial treatment for these infections\n* CD-SPECIFIC INCLUSION: Mild Disease Cohort: Patients must be in clinical remission as defined by a Crohn's Disease Activity Index (CDAI) \\\u003C 150 either without treatment or on a 5-ASA derivative, probiotic, antibiotics, or following fecal transplant\n* CD-SPECIFIC INCLUSION: Moderate Disease Cohort: Patients must be in clinical remission as defined by a CDAI \\\u003C 150 on 6-mercaptopurine, azathioprine, methotrexate, rectal hydrocortisone, budesonide, or one of these medications in combination with any of the medications listed in the Mild cohort\n* CD-SPECIFIC INCLUSION: Severe Disease Cohort (A or B): Patients must either A) be in clinical remission as defined by a CDAI \\\u003C 150 on biologic therapy targeting TNF-α (infliximab, adalimumab, certolizumab pegol), IL-12\u002F23p40 (ustekinumab), α4β7 integrin (vedolizumab), or one of these biologic therapies in combination with any of the medications listed in the Mild or Moderate cohort, or B) have mild active disease as defined by a CDAI of 150 to 220 on one of medications or combination of medications defined for the Moderate or Mild cohort\n* OTHER AUTOIMMUNE DISEASES- NS-SPECIFIC INCLUSION: For other autoimmune diseases that cannot be classified, the eligibility criteria will be determined by the managing rheumatologist or other autoimmune disease specialist, based on the clinical judgement and current American College of Radiology (ACR) classification guidelines or other relevant guidelines, as per the disease category in question\n* OTHER AUTOIMMUNE DISEASES- NS-SPECIFIC INCLUSION: For giant cell arteritis (GCA), patients must have had positive temporal artery biopsy for GCA and abnormal erythrocyte sedimentation rate (ESR) at time of diagnosis\n* OTHER AUTOIMMUNE DISEASES- NS-SPECIFIC INCLUSION: For polymyalgia rheumatica (PMR), patients must have clinical diagnosis in addition to elevated inflammatory markers including (ESR, C reactive protein \\[CRP\\])\n* OTHER AUTOIMMUNE DISEASES- NS-SPECIFIC INCLUSION: Patients can be in remission (with no glucocorticoids or immunosuppressive medications) or have low-moderate activity, which is defined as being on prednisone ≤ 10 mg or equivalent\n* MS-SPECIFIC INCLUSION: Patients must meet 2017 McDonald criteria for the diagnosis of MS (Thompson AJ, et al. Diagnosis of multiple sclerosis: 2017 revision of the McDonald criteria. Lancet Neurol. 17(2):162-173.)\n* MS-SPECIFIC INCLUSION: Patients with MS can be in remission and can have a history of being on immunomodulatory agents, but at the time of entry into the clinical trial, patients should be off any concurrent MS therapy for at least 2 weeks. Patients receiving concomitant interferon gamma (IFN-γ treatment) will be permitted in the study\n* SJS-SPECIFIC INCLUSION: SjS diagnosed by a rheumatologist or oral medicine provider. The patient should meet the American-European Consensus Criteria for Sjögren's Syndrome (Vitali, et al., 2002). If on treatment, the patient may only be on hydroxychloroquine and prednisone ≤ 10 mg or equivalent\n* PSO\u002FPSA-SPECIFIC INCLUSION: Patients with known PsO as diagnosed by a dermatologist or PsA by a rheumatologist and\u002For by Classification for Psoriatic Arthritis (CASPAR) criteria (Tillett et al., 2012)\n* PSO\u002FPSA-SPECIFIC INCLUSION: Patients must have stable disease as determined by the investigator with no change in systemic therapy and\u002For biologic therapy for at least 3 months, except for those on tumor necrosis factor (TNF) inhibitors. In the case of TNF inhibition, patients may have transitioned to an alternative biologic therapy with stable disease for at least 4 weeks. For PsA, no change in corticosteroid therapy for at least 1 month prior to baseline and dose must be 10 mg or less\n* PSO\u002FPSA-SPECIFIC INCLUSION: Patients may be on any concurrent therapy for PsO or PsA unless specifically excluded\n\nExclusion Criteria:\n\n* Patients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (AEs) due to agents administered more than 4 weeks earlier have not resolved or stabilized. Palliative (limited-field) radiation therapy (RT) is permitted (2 week washout from start of treatment), if all of the following criteria are met:\n\n  * Repeat imaging demonstrates no new sites of bone metastases\n  * The lesion being considered for palliative radiation is not a target lesion\n* Patients with prior therapy with an anti-PD-1 or anti-PD-L1\n* Patients with prior allogeneic hematologic transplant\n* Patients who are receiving any other anticancer investigational agents\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* UC-SPECIFIC EXCLUSION: Patients who have received ipilimumab treatment\n* UC-SPECIFIC EXCLUSION: Prior colectomy\n* UC-SPECIFIC EXCLUSION: Concurrent primary sclerosing cholangitis (PSC). Patients with PSC can be enrolled on the Other Autoimmune Diseases Cohorts\n* UC-SPECIFIC EXCLUSION: Patients on empiric immunosuppressive treatment without any clinical workup\n* CD-SPECIFIC EXCLUSION: Known untreated abscesses, untreated and symptomatic strictures, short gut physiology, or isolated jejunal disease\n* CD-SPECIFIC EXCLUSION: Patients who have received ipilimumab treatment\n* CD-SPECIFIC EXCLUSION: Patients on empiric immunosuppressive treatment without any clinical workup\n* MS-SPECIFIC EXCLUSION: Patients with MS cannot have medical contraindications to gadolinium-enhanced magnetic resonance imaging (MRI)",{"count":271,"type":19},300,[273],"PHASE1","This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from where it first started (primary site) to nearby tissue, lymph nodes, or distant parts of the body (advanced), to other places in the body (metastatic) or cannot removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib blocks certain proteins, which may help keep tumor cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Cabozantinib is a type of tyrosine kinase inhibitor and a type of angiogenesis inhibitor. Chemotherapy drugs, such as platinum containing therapies and fluoropyrimidine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab alone and in combination with other treatments, including ipilimumab, cabozantinib, platinum containing therapy, or fluoropyrimidine, may be safe, tolerable, and\u002For effective in treating patients with autoimmune disorders and advanced, metastatic, or unresectable cancer.",[276,277,278,24,279,25,280,281,282,283,284,285,286,287],"Autoimmune Disease","Crohn Disease","Dermatomyositis","Inflammatory Bowel Disease","Multiple Sclerosis","Psoriasis","Psoriatic Arthritis","Rheumatoid Arthritis","Sjogren Syndrome","Systemic Lupus Erythematosus","Systemic Scleroderma","Ulcerative Colitis","2026-07-30",{"date":290,"type":32},"2026-07-31",{"date":292,"type":32},"2019-07-16",{"date":294,"type":19},"2028-03-30",{"name":296,"class":297},"National Cancer Institute (NCI)","NIH",52,{"id":300,"slug":301,"hasResults":12,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":12,"sex":16,"minAge":73,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":308,"conditions":309,"keywords":4,"overallStatus":314,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":40},"100429392","adoption-of-audio-recording-in-the-outpatient-supportive-care-center-100429392","NCT04871477","Adoption of Audio Recording in the Outpatient Supportive Care Center","The Adoption of Audio Recording in the Outpatient Supportive Care Center","Inclusion Criteria:\n\n* Patients with the diagnosis of advanced cancer as defined as locally advanced, recurrent or metastatic cancer. Both solid and liquid tumors are eligible for the study\n* Patients who are seen in the outpatient supportive care center at M.D. Anderson Cancer Center\n* Patients who have access to a recording device or cellphone with recording technology\n* Patients who can be contacted 7 to 11 days from the clinic visit that the recording took place\n* Patients who can sign informed consent\n* Patients who are able to read and write in English\n* Patients 18 years or older\n\nExclusion Criteria:\n\n* Patients who have been diagnosed with delirium or cognitive impairment. This will be defined by chart review along with review of the MD Anderson Symptom Inventory (MDAS) the day of clinic visit. An MDAS of 7 or greater will be considered to define delirium in this study\n* Patients who are unwilling to sign informed consent\n* Patients who have used audio recordings before in clinic visits\n* Patients who have severe hearing impairments without access to assisted devices or programs to aid in listening to the recorded material",{"count":307,"type":19},200,"This study evaluates how patients feel about having an audio recording of their visit to help remember information given to them and share that information with family members and\u002For caregivers not present during a clinic visit. Information from this study may help evaluate the effectiveness of using technology to help improve patient care by recording consultation recommendations.",[310,24,311,312,313],"Advanced Malignant Solid Neoplasm","Locally Advanced Malignant Solid Neoplasm","Metastatic Malignant Solid Neoplasm","Recurrent Malignant Solid Neoplasm","NOT_YET_RECRUITING","2026-07-15",{"date":317,"type":32},"2026-07-16",{"date":319,"type":19},"2026-12-30",{"date":321,"type":19},"2027-01-30",{"name":38,"class":39},{"id":324,"slug":325,"hasResults":12,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":12,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":52,"phases":332,"briefSummary":334,"conditions":335,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":337,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":40},"100417196","phase-2-baloxavir-and-oseltamivir-for-the-treatment-of-severe-influenza-infection-in-immunocompromised-patients-100417196","NCT04712539","Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients","Efficacy of Combination Baloxovir and Oseltamivir Therapy in Influenza Infected Immunocompromised Hosts","Inclusion criteria:\n\n1. Hematopoeitic cell transplant recipients OR hematological malignancy patients\n2. Diagnosed with influenza ⱡ\n3. Evidence of LRTI\\* or high risk upper respiratory tract infection (URTI)\\*\\*\n\nⱡ A positive multiplex PCR for influenza is required to confirm a diagnosis of influenza infection.\n\n\\* LRTI will be defined as influenza cases that have evidence of disease below the level of the trachea on either imaging only (possible LRTI), imaging and microbiological evidence of lower airway disease with a bronchoscopy (probable LRTD) or pathological evidence of disease via biopsy (proven LRTI).\n\n\\*\\* High risk URI will be defined as those cases of influenza that do not have microbiological nor radiological evidence of LRTI, yet they have an immunodeficiency scoring index (ISI) of 3 or greater as defined by Shah D et al (19) for HCT recipients or severe neutropenia (ANC ≤500 cells\u002Fml) and\u002For lymphopenia (ALC ≤200 cells\u002Fml) for HM patients.\n\nExclusion criteria:\n\n1. Patient requires mechanical ventilation at time of enrollment\n2. Patient is younger than the age of 12 years old\n3. The patient is unable to tolerate oral therapy\n4. The patient is pregnant at screening ( Positive serum β-HCG (beta-human chorionic gonadotropin) test for women of child-bearing potential).\n5. The patient is on a prohibited medication. These include Influenza antiviral drugs with the exception of oseltamivir and baloxavir (such as peramivir, laninamivir, zanamivir, rimantadine, umifenovir or amantadine) and herbal therapies.\n6. The patient is unable to consent will be excluded",{"count":331,"type":19},60,[333],"PHASE2","This phase II trial studies the effect of baloxavir in combination with oseltamivir in treating severe influenza infection in patients who have previously received a hematopoietic (blood) stem cell transplant or have a hematological malignancy. Baloxavir is an antiviral drug that inhibits the growth of influenza virus, reduces viral load and prevents further influenza infection. Osetamivir is an antiviral drug that blocks enzymes on the surfaces of influenza viruses, interfering with cell release of complete viral particles. Giving baloxavir in combination with oseltamivir may shorten or decrease the intensity of influenza infection compared to oseltamivir alone.",[24,336],"Influenza",{"date":317,"type":32},{"date":339,"type":32},"2021-10-11",{"date":341,"type":19},"2028-02-28",{"name":38,"class":39},{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":16,"minAge":73,"maxAge":152,"enrollmentInfo":350,"targetDuration":4,"studyType":52,"phases":351,"briefSummary":352,"conditions":353,"keywords":365,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":40},"100337247","phase-1-211at-bc8-b10-followed-by-donor-stem-cell-transplant-in-treating-patients-with-relapsed-or-refractory-high-risk-acute-leukemia-or-myelodysplastic-syndrome-100337247","NCT03670966","211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome","A Phase I\u002FII Study Evaluating Escalating Doses of 211At-Labeled Anti-CD45 MAb BC8-B10 (211At-BC8-B10) Followed by Related Haplo-Identical Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Leukemia or Myelodysplastic Syndrome (MDS)","Inclusion Criteria:\n\n* Patients must have AML, ALL, high-risk MDS, or MPAL (also known as biphenotypic) meeting one of the following descriptions:\n\n  * AML, ALL, or MPAL in first remission with evidence of measurable residual disease (MRD) by flow cytometry;\n  * AML, ALL, or MPAL beyond first remission (i.e., having relapsed at least one time after achieving remission in response to a treatment regimen);\n  * AML, ALL, or MPAL representing primary refractory disease (i.e., having failed to achieve remission at any time following one or more prior treatment regimens);\n  * AML evolved from myelodysplastic or myeloproliferative syndromes;\n  * MDS expressed as refractory anemia with excess blasts (RAEB)\n  * Chronic myelomonocytic leukemia (CMML) by French-American-British (FAB) criteria.\n* Patients not in remission must have CD45-expressing leukemic blasts. Patients in remission do not require phenotyping and may have leukemia previously documented to be CD45 negative (because in remission patients, virtually all antibody binding is to non-malignant cells which make up \\>= 95% of nucleated cells in the marrow).\n* Patients must be \\>= 18 and =\\\u003C 75 years of age.\n* Patients should have a circulating blast count of less than 10,000\u002Fmm\\^3 (control with hydroxyurea or similar agent is allowed).\n* Patients must have an estimated creatinine clearance greater than 50\u002Fml per minute by the following formula (Cockcroft-Gault). Serum creatinine value must be within 28 days prior to registration.\n* Total bilirubin within normal limits\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C 2 times the upper limit of normal.\n* Eastern Cooperative Oncology Group (ECOG) \\\u003C 2 or Karnofsky \\>= 70.\n* Patients must be free of uncontrolled infection.\n* Patients with prior non-myeloablative or reduced-intensity conditioning allogeneic-HCT must have no evidence of ongoing GVHD and be off all immunosuppression for at least 6 weeks at time of enrollment.\n* Patients must have normal elastography.\n* If ferritin is elevated, patient must have less than 7 mg\u002Fg liver iron concentration on liver T2 magnetic resonance imaging (MRI).\n* Patients should have an official gastrointestinal (GI) consult prior to the transplant for full evaluation.\n* Patients must have a related donor who is identical for one HLA haplotype and mismatched at the HLA-A, -B or DRB1 loci of the unshared haplotype with the exception of single HLA-A, -B or DRB1 mismatches.\n* DONOR: Donors must meet HLA matching criteria as well as standard Seattle Cancer Care Alliance (SCCA) criteria for PBSC or bone marrow donation. Preference should be given to donors who are mismatched at the HLA-A, -B and -DRB1 loci.\n\nExclusion Criteria:\n\n* Patients may not have symptomatic coronary artery disease and may not be on cardiac medications for anti-arrhythmic or inotropic effects.\n* Left ventricular ejection fraction \\\u003C 45%.\n* Corrected diffusion capacity of the lung for carbon monoxide (DLCO) \\\u003C 35% or receiving supplemental continuous oxygen. When pulmonary function tests (PFTs) cannot be obtained, the 6-minute walk test (6MWT, also known as exercise oximetry) will be used: Any patient with oxygen saturation on room air of \\\u003C 89% during a 6MWT will be excluded\n* Liver abnormalities: fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction as evidenced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis, or symptomatic biliary disease.\n* Patients who are known to be seropositive for human immunodeficiency virus (HIV).\n* Perceived inability to tolerate diagnostic or therapeutic procedures.\n* Active central nervous system (CNS) leukemia at time of treatment.\n* Patients with prior myeloablative allogeneic-HCT.\n* Women of childbearing potential who are pregnant (beta human chorionic gonadotropin \\[B-HCG\\]+) or breast feeding.\n* Fertile men and women unwilling to use contraceptives during and for 12 months post-transplant.\n* Inability to understand or give an informed consent.\n* Allergy to murine-based monoclonal antibodies.\n* Known contraindications to radiotherapy.",{"count":75,"type":19},[273,333],"This phase I\u002FII trial studies the side effects and best dose of a radioactive agent linked to an antibody (211At-BC8-B10) followed by donor stem cell transplant in treating patients with high-risk acute leukemia or myelodysplastic syndrome that has come back (recurrent) or isn't responding to treatment (refractory). 211At-BC8-B10 is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving chemotherapy and total body irradiation before a stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can attack the body's normal cells, called graft versus host disease. Giving cyclophosphamide, mycophenolate mofetil, and tacrolimus after a transplant may stop this from happening.",[354,355,356,357,358,359,360,361,362,363,364,24],"Acute Lymphoblastic Leukemia in Remission","Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","Acute Myeloid Leukemia in Remission","Chronic Myelomonocytic Leukemia","Myelodysplastic Syndrome With Excess Blasts","Recurrent Acute Lymphoblastic Leukemia","Recurrent Acute Myeloid Leukemia","Refractory Acute Lymphoblastic Leukemia","Refractory Acute Myeloid Leukemia","Recurrent Mixed Phenotype Acute Leukemia","Refractory Mixed Phenotype Acute Leukemia",[366,367,368],"Lymphoid Leukemia","Myeloid and Monocytic Leukemia","Other Hematopoietic","2026-06-17",{"date":371,"type":32},"2026-06-22",{"date":373,"type":32},"2019-07-10",{"date":375,"type":19},"2029-10-20",{"name":377,"class":39},"Fred Hutchinson Cancer Center",{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":16,"minAge":73,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":387,"conditions":388,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":401,"locationsCount":40},"100132279","data-collection-for-the-assessment-of-acute-and-late-normal-tissue-in-patients-treated-with-proton-therapy-100132279","NCT00991094","Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy","Data Collection to Assess Acute and Late Normal Tissue Sequelae in Proton Therapy for Adults","Inclusion Criteria:\n\n* All patients scheduled for radiation treatment with protons at UTMDACC are eligible for this protocol\n* Patients must sign a study-specific consent form prior to study entry\n\nExclusion Criteria:\n\n* Patients who are unable or unwilling to attend the required periodic follow-ups either at M.D. Anderson or at a different site",{"count":386,"type":19},5000,"This study collects information on the side effects of proton therapy and detailed information on the proton therapy treatment plan itself. This may help researchers develop methods to predict the risk of side effects for future patients and learn the long-term benefit of proton therapy.",[389,390,391,166,24,392,393,394,25],"Breast Carcinoma","Esophageal Carcinoma","Genitourinary System Carcinoma","Lung Carcinoma","Malignant Central Nervous System Neoplasm","Malignant Digestive System Neoplasm","2026-06-10",{"date":397,"type":32},"2026-06-12",{"date":399,"type":32},"2005-05-27",{"date":242,"type":19},{"name":38,"class":39},{"id":403,"slug":404,"hasResults":12,"nctId":405,"briefTitle":406,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":133,"sex":16,"minAge":408,"maxAge":4,"enrollmentInfo":409,"targetDuration":4,"studyType":52,"phases":411,"briefSummary":412,"conditions":413,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":40},"100554588","increasing-knowledge-and-interest-in-cancer-clinical-trials-100554588","NCT06501040","Increasing Knowledge and Interest in Cancer Clinical Trials","Inclusion Criteria:\n\n* Individuals aged 21 and older\n* Participants will be identified through Karmanos Cancer Institute's (KCI) clinical treatment center\n* Participants will be identified through community-based KCI-sponsored events\n* Participants will have voiced an interest to participate followed by an Informed consent\n\nExclusion Criteria\n\n* none","21 Years",{"count":410,"type":19},384,[97],"This trial investigates how well a video-based clinical trial education session works in increasing knowledge and interest in cancer clinical trials among individuals in the metropolitan Detroit region of the Karmanos Cancer Institute (KCI) catchment area. This educational activity may help researchers learn more about individuals' awareness of clinical trials, knowledge, and intention to participates in a clinical trial.",[24,25],"2026-06-08",{"date":395,"type":32},{"date":417,"type":32},"2020-06-12",{"date":419,"type":19},"2028-02-01",{"name":421,"class":39},"Hayley Thompson",{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":12,"sex":16,"minAge":73,"maxAge":429,"enrollmentInfo":430,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":432,"conditions":433,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":440,"locationsCount":40},"100404823","the-effect-of-covid-19-pandemic-on-adolescent-and-young-adult-cancer-patients-and-survivors-100404823","NCT04551378","The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors","Impacts of Coronavirus Disease 2019 (COVID-19) Pandemic on Adolescent and Young Adult (AYA) Cancer Patients and Survivors","Inclusion Criteria:\n\n* PATIENT COHORT INCLUSION:\n* Initial cancer diagnosis between the ages of 15 to 39\n* Received any cancer treatment at MD Anderson Cancer Center with data available in the MD Anderson Cancer Center Tumor Registry\n* For questionnaire provision: confirmed alive at time of contact\n\nExclusion Criteria:\n\n* PATIENT COHORT EXCLUSION:\n* Inability to complete questionnaires in English\n* Seen at MD Anderson for a second opinion or non-treatment related visit","39 Years",{"count":431,"type":19},600,"The study investigates how the COVID-19 pandemic has impacted the psychological, financial, physical, and social well-being of adolescent and young adult (AYA) cancer patients and survivors. AYA cancer survivors have inferior long-term survival compared to the general population, and the negative impact of the global COVID-19 pandemic may be even higher in this vulnerable group. The information gained from this study may provide an opportunity to determine the self-reported COVID-19 specific psychological distress in AYA cancer survivors, and may lead to the development of a targeted intervention to improve physical and psychosocial health for AYA cancer patients and survivors.",[138,24,25],"2026-05-29",{"date":436,"type":32},"2026-06-02",{"date":438,"type":32},"2020-07-13",{"date":106,"type":19},{"name":38,"class":39},{"id":442,"slug":443,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":4,"eligibilityCriteria":447,"healthyVolunteers":12,"sex":16,"minAge":73,"maxAge":4,"enrollmentInfo":448,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":449,"conditions":450,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":471},"100490236","collecting-blood-and-tissue-sample-donations-for-research-for-hivaids-related-cancers-100490236","NCT05663502","Collecting Blood and Tissue Sample Donations for Research for HIV\u002FAIDS-Related Cancers","Biospecimen Collection and Donation to the AIDS and Cancer Specimen Resource (ACSR): A Companion Protocol to AMC Trials","Inclusion Criteria:\n\n* Participants must be at least 18 years of age\n* Participant must be HIV- positive and have a diagnosed malignancy. If participants are HIV-negative, they must have a newly diagnosed or recurrent malignancy that has an established scientific connection (e.g., shared etiology) to an AIDS- associated malignancy such as:\n\n  * classic Kaposi sarcoma\n  * transplant-associated Kaposi sarcoma,\n  * anal cancer,\n  * multicentric Castleman's disease,\n  * Epstein Barr Virus (EBV) -positive lymphoma\n  * plasmablastic lymphoma\n  * Hodgkin's lymphoma.\n\n    * For participants that are HIV-positive, HIV infection must be documented by means of any one of the following: :\n\n      * Documentation of HIV diagnosis in the medical record by a licensed health care provider;\n      * Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider (Documentation may be a record of an ART prescription in the participant's medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant's name. Receipt of at least two agents is required; each component agent of a multi-class combination ART regimen will be counted toward the 2-agent requirement, excepting receipt of a pre-exposure prophylaxis (PrEP) regimen alone \\[e.g., Truvada\\], which is exclusionary);\n      * HIV ribonucleic acid (RNA) detection by a licensed HIV RNA assay demonstrating \\> 1000 RNA copies\u002FmL;\n      * Any licensed HIV screening antibody and\u002For HIV antibody\u002Fantigen combination assay confirmed by a second licensed HIV assay such as a HIV Western blot confirmation or HIV rapid multispot antibody differentiation assay.\n* Participants with HIV infection, regardless of participation in an AMC clinical trial, must have a diagnosis of cancer, cancer or a condition that places them at a higher risk of cancer.\n* The investigator determines that the participant (or his\u002Fher legally authorized representative \\[LAR\\]) has the ability to provide informed consent and the participant or LAR provides written informed consent.",{"count":307,"type":19},"This study collects blood and tissue samples for research of human immunodeficiency virus (HIV)\u002Facquired immunodeficiency syndrome (AIDS)-related cancers. Collecting blood and tissue samples and studying biomarkers in the laboratory may help doctors to learn how are biologic or genetic factors related to HIV and cancers that occur commonly in people living with HIV.",[451,24,452,453,454,25,455,456,457,458,459,460],"Anal Carcinoma","HIV Infection","Kaposi Sarcoma","Lymphoma","Multicentric Castleman Disease","Plasmablastic Lymphoma","Recurrent Kaposi Sarcoma","Recurrent Lymphoma","Recurrent Plasmablastic Lymphoma","Transplant-Related Kaposi Sarcoma","2026-05-28",{"date":463,"type":32},"2026-06-01",{"date":465,"type":32},"2023-05-10",{"date":467,"type":19},"2035-08-31",{"name":469,"class":470},"AIDS Malignancy Consortium","NETWORK",8,{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":133,"sex":16,"minAge":408,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":481,"conditions":482,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":40},"100443439","formulating-expert-consensus-guidelines-in-cancer-care-using-the-delphi-method-100443439","NCT05054413","Formulating Expert Consensus Guidelines in Cancer Care Using the Delphi Method","Key Elements for Standardized Reporting in Prostate Cancer Management: An Expert Delphi Consensus Study","Inclusion Criteria:\n\n* Age 21 and above\n* Board certification in Radiation Oncology, Radiation Physics, Urology, and\u002For Medical Oncology\n* Maintenance of an active practice that includes prostate cancer patients\n* English speaking\n\nExclusion Criteria:\n\n* Medical providers that are not board certified in the professions and\u002For those who do not treat prostate cancer\n* Prisoners, children, and adults unable to consent to participation will also be excluded\n* No exclusions were made based on sex, age, racial\u002Fethnic background, or pregnancy status",{"count":480,"type":19},10,"This study formulates consensus agreement on clinical key elements related to prostate cancer care that are critical for standardization and global reported using a robust Delphi technique, completely remote and electronic. The goal of this survey study is to have a panel of specialty-specific experts create a consensus agreement on a minimum set of key data elements for use in standardized reports. These recommendations would be used to develop standardized methods to report key data in electronic health records to better manage cancer patients at time of diagnosis, treatment, follow up, and into survivorship.",[24,25],"2026-05-22",{"date":485,"type":32},"2026-05-26",{"date":487,"type":32},"2021-04-15",{"date":489,"type":19},"2030-08-01",{"name":38,"class":39},{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":495,"acronym":4,"eligibilityCriteria":496,"healthyVolunteers":12,"sex":16,"minAge":73,"maxAge":4,"enrollmentInfo":497,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":499,"conditions":500,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":40},"100440111","neurocognitive-outcomes-after-whole-brain-radiation-therapy-for-hematologic-malignancies-100440111","NCT05011045","Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies","Inclusion Criteria:\n\n* Age 18 years or older\n* Treatment with radiation therapy to the brain for a hematologic malignancy (ex. primary central nervous system lymphoma \\[PCNSL\\], secondary central nervous system lymphoma \\[SCNSL\\], leukemia, myeloma)\n* Proficient and capable of completing tests in English\n* Patients with claustrophobia are eligible if the claustrophobia is managed with medication\n* Patients with cognitively-impairment are eligible if the impairment is managed with medication\n* Patients who are pregnant",{"count":498,"type":19},100,"This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hematologic malignancies). This may help researchers learn more about the effects of whole brain radiation therapy on memory and thinking in patients with blood cancer.",[501,24,502,454,503,504],"Central Nervous System Lymphoma","Leukemia","Plasma Cell Myeloma","Secondary Central Nervous System Lymphoma","2026-05-18",{"date":507,"type":32},"2026-05-20",{"date":509,"type":32},"2020-01-09",{"date":511,"type":19},"2026-10-31",{"name":38,"class":39},{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":4,"eligibilityCriteria":519,"healthyVolunteers":12,"sex":16,"minAge":520,"maxAge":73,"enrollmentInfo":521,"targetDuration":4,"studyType":52,"phases":523,"briefSummary":525,"conditions":526,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":527,"lastUpdatePostDateStruct":528,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":534,"locationsCount":5},"100493938","phase-3-a-study-of-the-drug-letermovir-as-prevention-of-cytomegalovirus-infection-after-stem-cell-transplant-in-pediatric-patients-100493938","NCT05711667","A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients","Letermovir Prophylaxis for Cytomegalovirus in Pediatric Hematopoietic Cell Transplantation","Inclusion Criteria:\n\n* \\>= 2 years and \\\u003C 18 years at the time of enrollment\n* Weight must be \\>= 6 kg at the time of enrollment\n* Planned allogeneic HCT (bone marrow, peripheral blood stem cell, or cord blood transplant)\n* Patient must be CMV sero-positive (i.e., recipient CMV immunoglobulin G positive)\n\n  * Note: If a patient has hypogammaglobulinemia but has previously been documented as CMV sero-positive, that is acceptable for study inclusion. For all patients already confirmed to be CMV IgG seropositive, repeat testing is not required within 7 days prior to enrollment. However, the laboratory data determining eligibility must be available in the patient's medical\u002Fresearch record for verification\n* Patient is eligible for entry only if it is feasible for plasma CMV PCR testing to be sent and resulted within the protocol mandated time period\n\n  * Reminder: To limit the likelihood of positive plasma CMV PCR post-enrollment and prior to start of study treatment period, it is recommended that patient enrollment proceed after patients start their transplant preparative regimen\n* Patient must have a performance status corresponding to Lansky\u002FKarnofsky scores \\> 50\n\n  * Note: Use Lansky for patients =\\\u003C 16 years of age and Karnofsky for patients \\> 16 years of age. For further reference, see performance status scales scoring under the standard sections for protocols among protocol reference materials provided on the Children's Oncology Group (COG) member website: https:\u002F\u002Fmembers.childrensoncologygroup.org\u002Fprot\u002Freference\\_materials.asp\n* Estimated glomerular filtration rate \\> 10 mL\u002Fmin\u002F1.73 m\\^2 and not receiving dialysis\n* Direct bilirubin =\\\u003C 2 mg\u002FdL and serum glutamate-pyruvate transaminase (SPGT) (alanine transaminase \\[ALT\\]) =\\\u003C10 x upper limit of normal (ULN) for age\n\n  * Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U\u002FL\n\nExclusion Criteria:\n\n* Expected inability to tolerate oral formulation of letermovir\n* Hypersensitivity to letermovir or any component of the formulation\n* History of CMV end organ disease within 6 months (180 days) prior to enrollment\n\n  * Note: CMV end organ disease based on proposed definitions by Ljungman et al. and inclusive of proven, probable or possible disease\n* Receipt of prior allogeneic HCT within one year of study enrollment\n* Planned prophylactic administration of other anti-CMV medications or cellular products during the study, including:\n\n  * High dose acyclovir (defined as doses \\>= 1500 mg\u002Fm\\^2 IV or \\>= 3200 mg oral (patients \\>= 40 kg) or \\>= 2400 mg\u002Fm\\^2 (patients \\\u003C 40 kg) per day)\n  * High dose valacyclovir (defined as doses \\>= 3000 mg\u002Fday in patients \\> 20 kg)\n  * Foscarnet\n  * Ganciclovir\n  * Valganciclovir\n  * CMV-directed cytotoxic T lymphocytes\n* Planned receipt of the following contraindicated medications during the study treatment period; contraindicated medications must be discontinued at least 14 days prior to Day +1\n\n  * Contraindicated medications for all patients:\n\n    * Pimozide\n    * Ergot alkaloids\n  * Contraindicated medications for patients planned to receive cyclosporine:\n\n    * Bosentan\n    * Pitavastatin\n    * Simvastatin\n* Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted in certain animal reproduction studies with letermovir. A pregnancy test is required for female patients of childbearing potential\n* Lactating females who plan to breastfeed their infants\n* Sexually active female patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their letermovir treatment and through at least 4 weeks after the last dose of letermovir.\n\n  * Note: No contraception measures are needed specifically during letermovir treatment for male trial participants who have pregnant or non-pregnant female partner(s) of reproductive potential. Contraception measures may be required for other aspects of the HCT procedure.\n* All patients and\u002For their parents or legal guardians must sign a written informed consent\n* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met","2 Years",{"count":522,"type":19},105,[524],"PHASE3","This phase III single arm trial determines whether taking prophylactic letermovir will reduce the likelihood of infection with cytomegalovirus (CMV) in children and adolescents after stem cell transplant compared to estimated rate of infection without prophylaxis. The treatments used to prepare for HCT reduce the body's natural infection-fighting ability and increase the likelihood of an infection with a virus called cytomegalovirus. \"Prophylaxis\" means to take a drug to prevent a disease or side effect. Letermovir is an antiviral drug that stops cytomegalovirus from multiplying and may prevent cytomegalovirus infection and make the disease less severe.",[24,25],"2026-05-01",{"date":529,"type":32},"2026-05-05",{"date":531,"type":32},"2024-07-11",{"date":533,"type":19},"2029-06-30",{"name":535,"class":470},"Children's Oncology Group",{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":4,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":16,"minAge":543,"maxAge":544,"enrollmentInfo":545,"targetDuration":4,"studyType":52,"phases":546,"briefSummary":547,"conditions":548,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":555,"locationsCount":86},"100414577","exercise-program-team-me-for-the-improvement-of-movement-and-mobility-in-pediatric-and-adolescent-and-young-adult-patients-with-cancer-undergoing-a-blood-stem-cell-transplant-100414577","NCT04678427","Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant","TEAM Me (Totally Excited About Moving, Mobility, and Exercise) Clinical Research Protocol","Inclusion Criteria:\n\n* Be admitted to an inpatient pediatric ward for the purpose of HSCT for the treatment of malignancy\n* Be greater than or equal to 6 years of age and less than 30 years of age\n* Participants or guardians are willing and able to give written informed consent either prior to admission or within 48 hours following admission and to comply with all of the study activities and procedures\n* Participants or guardians are willing and able to give written informed consent for protocol PA18-0130 (Pediatric Energy balance data repository protocol), companion protocol for the Fitbit application\u002Fassessment\n\nExclusion Criteria:\n\n* Patients whose clinical status precludes them from participating in any physical activity including but not limited to: declining respiratory status, hypoxia requiring high flow nasal cannula (Vapotherm), hypotension, and active bleeding.\n* At MD Anderson HSCT patients admitted to adult units for their transplant will not be eligible as TEAM Me is an established program on the G9 Pediatrics Unit only","6 Years","29 Years",{"count":331,"type":19},[97],"This clinical trial studies how well an exercise program (Totally Excited About Moving, Mobility, and Exercise \\[TEAM Me\\]) affects the exercise and dietary habits of pediatric and adolescents and young adults with cancer undergoing a blood stem cell transplant. TEAM Me is an exercise program that reinforces behavior, such as walking and other activities, using \"tokens\" (i.e. stickers) that can be redeemed for rewards. Participating in the exercise program may result in increased physical fitness, physical activity level, quality of life, and function in pediatric and adolescents and young adult patients with cancer.",[24,25],"2026-04-28",{"date":551,"type":32},"2026-05-04",{"date":553,"type":32},"2020-11-13",{"date":106,"type":19},{"name":38,"class":39},{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":16,"minAge":73,"maxAge":4,"enrollmentInfo":563,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":564,"conditions":565,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":573,"locationsCount":40},"100430688","outcomes-after-chimeric-antigen-receptor-therapy-and-radiation-therapy-for-hematologic-malignancies-100430688","NCT04888338","Outcomes After Chimeric Antigen Receptor Therapy and Radiation Therapy for Hematologic Malignancies","Outcomes After Chimeric Antigen Receptor Therapy (CAR-T) and Radiation Therapy (RT) for Hematologic Malignancies","Inclusion Criteria:\n\n* Age 18 years or older\n* Treatment with or intention to treat with radiation therapy, standard-of-care CAR-T cell therapy and\u002For standard-of-care bispecific therapy, within a 90 day window for a hematologic malignancy",{"count":498,"type":19},"This study collects information on outcomes after chimeric antigen receptor therapy and radiation therapy for hematologic malignancies. Collecting information from patients before, during, and after receiving chimeric antigen receptor therapy or radiation therapy may help doctors to optimize patient selection, dose, timing, and sequencing of these treatments.",[24],"2026-04-13",{"date":568,"type":32},"2026-04-16",{"date":570,"type":32},"2021-04-10",{"date":572,"type":19},"2026-11-14",{"name":38,"class":39},{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":4,"eligibilityCriteria":580,"healthyVolunteers":12,"sex":16,"minAge":73,"maxAge":4,"enrollmentInfo":581,"targetDuration":4,"studyType":52,"phases":582,"briefSummary":583,"conditions":584,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":40},"100452973","vertebroplasty-with-radiation-therapy-for-spine-metastatic-cancer-patients-with-indeterminate-lesion-sins-criteria-100452973","NCT05178472","Vertebroplasty With Radiation Therapy for Spine Metastatic Cancer Patients With Indeterminate Lesion (SINS Criteria)","Part A: Effect of Prophylactic Vertebroplasty Combined With Radiation Therapy for Spine Metastatic Cancer Patients With Indeterminate Lesion (SINS Criteria)","Inclusion Criteria:\n\n* At least 18 years of age and older with indeterminate Spine Metastasis.\n* All patients with histology that requires stereotactic RT as a part of their treatment.\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\\u003C 2\n* Disease visualized by CT or MRI\n* Prior radiation therapy will be allowed at the discretion of the Radiation Oncologist based on current standard operating procedures.\n* Tumor tissue from the core biopsy or resected site of disease will be collected, if available for biomarker analyses.\n* Four or less consecutive spinal segments involved by tumor. Or four or less separate spinal tumor targets with a minimum of one vertebral body separation\n* Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life questionnaire in either English or Spanish. The baseline assessment must be completed within required timelines. Inability (illiteracy in English or Spanish, loss of sight, or other equivalent reason) to complete the questionnaires will not make the patient ineligible for the study. However, ability but unwillingness to complete the questionnaires will make the patient ineligible\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years of age\n* Inability to get a standard MRI or CT myelogram for radiation treatment target delineation\n* Patients with prior radiation to the spinal segment to be treated may be included if the radiation dose can be delivered safely, per the treating radiation oncologist.\n* Patients with symptomatic spinal cord compression requiring emergent surgery\n* Pregnant or lactating women\n* Systemic therapy or immunosuppressive medications, excluding immunotherapy, within 3-14 days of radiation treatment, at the discretion of the treating radiation oncologist .\n* Patients with stable or unstable lesions based on SINS criteria",{"count":307,"type":19},[97],"This clinical trial studies the side effects of stereotactic radiosurgery and how well it works with or without vertebroplasty, separation surgery, or immunotherapy in patients with cancer that is radiation resistant and has spread to the spine (spinal metastases). Spinal metastases are rapidly progressive, have poor prognosis, are extremely difficult to treat, and can effect patient quality of life and overall health. Immunotherapy is a type of standard of care therapy to boost or restore the ability of the immune system to fight cancer. Stereotactic radiosurgery is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. A vertebroplasty is a procedure used to repair a bone in the spine that has a break caused by cancer, osteoporosis, or trauma. The purpose of this trial is to test different combinations of immunotherapy, stereotactic radiosurgery, and surgery to improve overall survival and quality of life in patients with spinal metastases.",[24,25,585],"Metastatic Malignant Neoplasm in the Spine","2026-04-03",{"date":588,"type":32},"2026-04-09",{"date":590,"type":32},"2023-03-27",{"date":592,"type":19},"2026-12-31",{"name":244,"class":39},{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":599,"acronym":4,"eligibilityCriteria":600,"healthyVolunteers":133,"sex":16,"minAge":601,"maxAge":4,"enrollmentInfo":602,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":604,"conditions":605,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":616,"locationsCount":40},"100301727","collection-of-immunology-specimens-from-patients-with-cancer-or-blood-disorders-and-healthy-volunteers-100301727","NCT03207854","Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers","Protocol for Immunology Specimen Collection From Cancer Patients, Patients With Hematologic Diagnoses, and Healthy Normal Controls","Inclusion Criteria:\n\n* All patients known to have cancer, an immune-mediated hematologic diagnosis, or a healthy normal volunteer\n* Definition of immune-mediated hematologic diagnosis: diagnoses for which immune dysfunction and\u002For immune system directed therapy (eg. aplastic anemia, autoimmune hemolytic anemia, immune thrombocytopenic purpura \\[ITP\\], etc.) are involved\n* Definition of healthy normal volunteer: persons lacking diagnoses of any type of cancer, diabetes, cardiovascular diseases, non-hematologic autoimmune disease (eg. systemic lupus erythematosus \\[SLE\\], rheumatoid arthritis \\[RA\\], Crohn's disease) and not taking any immunosuppressive medications\n* Patients must have been seen in the Norris Hospital and outpatient clinics, or the Los Angeles County (LAC)-University of Southern California (USC) Medical Center or outpatient clinics; healthy volunteers can be recruited without any physician visit appointments since their labs are strictly for clinical research and not for personal health issues unrelated to the project\n\nExclusion Criteria:\n\n* Unable to give informed consent to specimen collection\n* Known human immunodeficiency virus (HIV) positive status\n* Persons taking any type of immunosuppressive medication are excluded from participating as healthy normal volunteers\n* Any patient for whom specimen collection is judged to be unsafe (for example, for patients unable to establish venous access)","19 Years",{"count":603,"type":19},625,"This research trial collects and stores blood, tissue, and bone marrow specimens from patients with cancer or blood disorders, and healthy volunteers to study the immune system in a variety of different types of experiments, as well as associated clinical data as appropriate, focused on understanding mechanisms of immunotherapy.",[606,607,24,608,609],"Healthy Subject","Hematologic and Lymphocytic Disorder","Immune System Disorder","Malignant Neoplasm","2026-03-27",{"date":612,"type":32},"2026-04-02",{"date":614,"type":32},"2017-04-12",{"date":242,"type":19},{"name":617,"class":39},"University of Southern California",{"id":619,"slug":620,"hasResults":12,"nctId":621,"briefTitle":622,"officialTitle":622,"acronym":4,"eligibilityCriteria":623,"healthyVolunteers":12,"sex":16,"minAge":73,"maxAge":624,"enrollmentInfo":625,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":627,"conditions":628,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":632,"completionDateStruct":634,"leadSponsor":636,"locationsCount":638},"100447913","role-of-gut-microbiome-in-cancer-therapy-100447913","NCT05112614","Role of Gut Microbiome in Cancer Therapy","Inclusion Criteria:\n\n* Age 18-99\n* Diagnosis of cancer and undergoing cancer therapy or scheduled to start cancer therapy or undergoing stem cell transplant for any hematological condition\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* Vulnerable adults","99 Years",{"count":626,"type":19},3000,"This study examines how gut microbiome can affect cancer therapy in cancer patients undergoing cancer therapy or stem cell transplant. The human microbiome affects the way some cancer drugs are metabolized in the human body. Information from this study may help doctors improve the way cancer treatment is delivered, and increase its effectiveness and success.",[24,25],"2026-03-12",{"date":631,"type":32},"2026-03-16",{"date":633,"type":32},"2019-09-11",{"date":635,"type":19},"2030-10-01",{"name":637,"class":39},"Mayo Clinic",3]